Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

expectations regarding revenues, operating expenses, cash burn, and clinical developments and anticipated milestones are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the Company's ability to progress any product candidates in preclinical or clinical trials; the scope, rate and progress of its preclinical studies and clinical trials and other research and development activities; clinical trial results; even if the data from preclinical studies or clinical trials is positive, the product may not prove to be safe and efficacious; Novavax's pilot plant facility is subject to extensive validation and FDA inspections, which may result in delays and increases costs; the effect or outcome of the Company's decision to sell Estrasorb(R); the human capital and other costs Novavax will incur to exit the manufacturing facility; our ability to enter into future collaborations with industry partners and the terms, timing and success of any such collaboration; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain rights to technology; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; our ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity or debt financing or otherwise; general business conditions; competition; business abilities and judgment of personnel; and the availability of qualified personnel. Further information on the factors and risks that
'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... November 25, 2014 Whitehouse Laboratories ... joined the Morris County (New Jersey) Chamber of ... a leading business organization in the North Jersey ... further engage some key clients in the pharmaceutical ... the geographic area. Membership enables Whitehouse Laboratories a ...
(Date:11/26/2014)... Global biostimulants market is expected ... an estimated CAGR of 12.5%. In order to ... with least ecological impacts, farmers are looking to ... crop yield more effectively & efficiently. Biostimulants are ... the return on investments. , Leading companies in ...
(Date:11/26/2014)... , 25 novembre 2014 Theravalues Corporation est ... le marché européen au salon Hi Europe 2014 ... ). Curcumine la plus biodisponible ... amorphe (non-cristalline) à des ingrédients approuvés par les ... pigment jaune présent dans la racine de curcuma ...
(Date:11/24/2014)... November 24, 2014 Five American ... Rashid Al Maktoum Awards for Medical Sciences", in its ... United Arab Emirates , on 15 December 2014. ... The Carter Center which won the Hamdan ... involved in numerous programs that aim to improve health ...
Breaking Biology Technology:Whitehouse Laboratories Joins Morris County Chamber of Commerce 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3Five US Winners Among Recipients of Hamdan Medical Awards 2
... the College,s history, BRONX, N.Y., May 13 ... University today announced that it has received a ... largest in the College,s 53-year history,-- from Ruth ... the Gottesmans is,available., (Photo: http://www.newscom.com/cgi-bin/prnh/20080513/NYTU059-a ), ...
... Milestone, NEW YORK, May 13 NeoStem, Inc. ... processing and long-term,storage of adult stem cells for future ... for a new stem cell collection center in Coral,Gables, ... MBA, NeoStem,s Chairman and Chief Executive Officer,commented: "Securing the ...
... Pacific Time, SAN DIEGO, May 13 SGX ... for the first quarter,of 2008. For the three months ... $17.0 million and net income of $3.7 million. The ... that was,attributable to the one-time recognition of the remaining ...
Cached Biology Technology:Albert Einstein College of Medicine Receives $25-Million Gift to Support Stem Cell and Epigenomic Research and Clinical Skills Training 2Albert Einstein College of Medicine Receives $25-Million Gift to Support Stem Cell and Epigenomic Research and Clinical Skills Training 3Albert Einstein College of Medicine Receives $25-Million Gift to Support Stem Cell and Epigenomic Research and Clinical Skills Training 4Albert Einstein College of Medicine Receives $25-Million Gift to Support Stem Cell and Epigenomic Research and Clinical Skills Training 5NeoStem to Expand Stem Cell Collection Center Network to Florida 2NeoStem to Expand Stem Cell Collection Center Network to Florida 3SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update 2SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update 3SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update 4SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update 5SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update 6SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update 7SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update 8
(Date:11/6/2014)... cancer deaths occur because of metastasis, yet progress ... been slow. , "It,s been particularly challenging to ... Gujral, research fellow in systems biology at Harvard ... detected until after they,ve already metastasized." , Gujral ... that should help researchers better understand how metastasis ...
(Date:11/5/2014)... has dedicated his career to understanding the Earth,s ... audience. , As deputy director and regional climatologist ... Desert Research Institute, Redmond has more than three ... dissemination of climate data to the general public. ... San Francisco on December 15-19, 2014 the American ...
(Date:11/4/2014)... School of Medicine announced today that it is ... by the Bill & Melinda Gates Foundation. ... and Reproductive Sciences; and Vice Chair of Research ... Medicine will pursue an innovative global health and ... Assess Fetal Neurodevelopment.", Grand Challenges Explorations (GCE) funds ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2Temple University School of Medicine receives Grand Challenges Explorations grant 2
... raise questions about why such losses matter and why ... traditionally responded to such questions by citing societal benefits ... like controlling pests and diseases, promoting the productivity of ... many others. Nevertheless, many of these presumed benefits are ...
... Battery technology hasn,t kept pace with advancements in portable ... One revolutionary concept being pursued by a team of ... capable of converting movement from humans or found in ... variable capacitor generators known as "dielectric elastomer generators" (DEGs) ...
... Rochelle, NY, April 6, 2011 The successful ... survival and reduce the risk of neurological consequences ... the premier issue of Therapeutic Hypothermia and ... published by Mary Ann Liebert, Inc. This groundbreaking ...
Cached Biology News:Precedent-setting evidence of the benefits of biodiversity 2Precedent-setting evidence of the benefits of biodiversity 3Precedent-setting evidence of the benefits of biodiversity 4Replacing batteries may become a thing of the past, thanks to 'soft generators' 2Hypothermia proven to improve survival and outcomes following out-of-hospital cardiac arrest 2Hypothermia proven to improve survival and outcomes following out-of-hospital cardiac arrest 3
... Digital shaking water bath, with a comprehensive ... and shaking water baths with seamless, splash-water ... The bright MULTI-DISPLAY (LED) indicating up to ... the lab. Advanced MICROPROCESSOR technology with PID ...
... an aqueous solution that contains a purified ... in a MOPS buffer (3-(N-Morpholino) propanesulfonic acid), ... contains a combination of 0.02% methylisothiazolone, 0.02% ... and Haas Company) as a preservative. ...
Request Info...
... Life Science FLA-7000 excels at fluorescent and ... documentation. It features four easy-to-access filters (filters ... filter for Imaging Plates) for upgrading flexibility. ... choice of four kinds of excitation laser ...
Biology Products: